SWOG clinical trial number
CTSU/A011801

The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in Her2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Open
Phase
III
Abbreviated Title
COMPASSHER2 RD: Double-Blind, Ph III Randomized Study of T-DM1 and Placebo v T-DM1 and Tucatinib
Activated
01/06/2021
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Breast Cancer
Symptom Control and Quality of Life

Treatment

Placebo Trastuzumab Emtansine Tucatinib

Eligibility Criteria Expand/Collapse

Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).

Other Clinical Trials

SWOG Clinical Trial Number
S2013

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Research Committee(s)
Symptom Control and Quality of Life
Activated
08/16/2021
Accrual
0%
Open
Phase
II
SWOG Clinical Trial Number
S1714

A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients

Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Lung Cancer
Early Therapeutics & Rare Cancers
Activated
03/01/2019
Accrual
100%
Open
Phase
SWOG Clinical Trial Number
S1600

A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

Research Committee(s)
Symptom Control and Quality of Life
Genitourinary Cancer
Activated
02/21/2019
Accrual
51%
Open
Phase
III